Guest
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: Join our Newsletter (scroll to the bottom of the page and sign up): Follow us on Twitter: The Psychedelic Investor: @PsycInvestor Psychedelic Spotlight: @PsycSpotlight Follow us on Instagram: @thepsychedelicinvestor @psycspotlight ❗❗❗ The Psychedelic Investor will be changing its name to PSYC Business very soon. Stay tuned for more updates! In today's episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results. MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today. Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. Matthias Liechti and Dr. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46
